Allergan, an AbbVie Inc. announced the U.S Food and Drug Administration (FDA) approval to expand the label of botox to include eight more muscles to treat adults with upper limb spasticity. The new approval was significant as it treated disabling neurological conditions influencing the quality of life of a patient.
Ipsen Group declared that Dysport, a clostridium botulinum type A toxin-haemagglutinin complex received the U.S. FDA. Dysport is the first UK botulinum toxin to get approved for pediatric spasticity therapy in upper and lower limbs.
Author Credits: Radhika Gupta, Shivam Bhutani